Action of ciprofibrate in type IIB hyperlipoproteinemia: Modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 8, 2003, Pages 3738-3746

  Guerin, Maryse ^a   Le Goff, Wilfried ^a   Frisdal, Eric ^a   Schneider, Séverine ^a   Milosavljevic, Dragana ^a   Bruckert, Eric ^a   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN 1; VERY LOW DENSITY LIPOPROTEIN 2;

ADULT; ARTICLE; ATHEROGENESIS; CELL LINE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPATOMA CELL; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERLIPOPROTEINEMIA TYPE 2B; LIPOPROTEIN BLOOD LEVEL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTERS; CLOFIBRIC ACID; CYCLIC AMP; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGES; MALE; MICE; MIDDLE AGED; PHENOTYPE; RATS; TUMOR CELLS, CULTURED;

EID: 0041883174     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030191     Document Type: Article

References (40)

1. Arad Y, Ramakrishnan R, Ginsberg HN 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 31:567-582
2. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ 2002 Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164:129-145
3. Packard CJ, Shepherd J 1997 Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542-3556
4. Chapman MJ, Guerin M, Bruckert E 1998 Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 19(Suppl A):A24-A30
5. Millar JS, Packard CJ 1998 Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol 9:197-202
6. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ 2000 Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197
7. O'Connor P, Feely J, Shepherd J 1990 Lipid lowering drugs. BMJ 300:667-672
8. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J 1993 Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 13:702-711
9. Bruckert E, Dejager S, Chapman MJ 1993 Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 100:91-102
10. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ 1996 Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 16:763-772
11. Nigon F, Lesnik P, Rouis M, Chapman MJ 1991 Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 32:1741-1753
12. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN 1998 Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138:217-225
13. Milosavljevic D, Griglio S, Le Naour G, Chapman MJ 2001 Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis 155:251-260
14. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenpera S, Taskinen MR 1993 Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis 102:79-89
15. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B 1994 Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269:31012-31018
16. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J 1995 Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750
17. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J 1996 PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348
18. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman MJ, Fruchard JC, Tedgui A, Najib-Fruchart J, Staels B 2000 CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411-2417
19. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J 1997 Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272:28210-28217
20. Guerin M, Egger P, Soudant C, Le Golf W, van Tol A, Dupuis R, Chapman MJ 2002 Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163:287-296
21. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM 1981 A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22:339-358
22. Guerin M, Dolphin PJ, Chapman MJ 1994 A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb 14:199-206
23. de la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G 1994 A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14:1056-1065
24. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC 1999 Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781-796
25. Sakr SW, Williams DL, Stoudt GW, Phillips MC, Rothblat GH 1999 Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim Biophys Acta 1438:85-98
26. Oram JF, Lawn RM, Garvin MR, Wade DP 2000 ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275:34508-34511
27. Guerin M, Egger P, Soudant C, Le Golf W, van Tol A, Dupuis R, Chapman MJ 2002 Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 43:1652-1660
28. Turpin G, Bruckert E 1996 Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis 124(Suppl):S83-S87
29. Aguilar-Salinas CA, Fanghanel-Salmon G, Meza E, Montes J, Gulias-Herrero A, Sanchez L, Monterrubio-Flores EA, Gonzales-Valdes H, Gomez Perez FJ 2001 Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. Metabolism 50:729-733
30. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP 1997 Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75
31. Rader DJ, Maugeais C 2000 Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Mol Med Today 6:170-175
32. Fruchart JC 2001 Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am J Cardiol 88:24N-29N
33. Desager JP, Horsmans Y, Vandenplas C, Harvengt C 1996 Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 124(Suppl):S65-S73
34. Newnham HH, Barter PJ 1992 Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim Biophys Acta 1125:297-304
35. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD 2002 Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 22:667-673
36. Barter PJ, Chang LB, Newnham HH, Rye KA, Rajaram OV 1990 The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high-density lipoproteins. Biochim Biophys Acta 1045:81-89
37. de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weiber G, Sakr SW, Phillips MC, Williams DL 1999 Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40:575-580
38. Fournier N, Atger V, Paul JP, de la Llera Moya M, Rothblat G, Moatti N 1999 Fractional efflux and net change in cellular cholesterol content mediated by sera from mice expressing both human apolipoprotein AI and human lecithin: cholesterol acyltransferase genes. Atherosclerosis 147:227-235
39. Fournier N, Atger V, Paul JL, Sturm M, Duverger N, Rothblat G, Moatti N 2000 Human apoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum. Arterioscler Thromb Vasc Biol 20:1283-1292
40. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denefle P, Staels B, Branellec D 1996 Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97:2408-2416